Saladax Biomedical, a company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced the company has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects. With the signing of this agreement, the companies have already initiated a new companion diagnostic project in an undisclosed field. Terms of the agreement were not disclosed.
Stock futures were fallingamid investor concerns the U.S. Federal Reserve may begin to taper its stimulus measures …